Postdoctoral Associate: Immunology, Gene Therapy, Molecular Biology
 Massachusetts General Hospital | |
 United States, Massachusetts, Boston | |
| 60 Blossom Street (Show on map) | |
 Jun 05, 2025 | |
|
Neutralizing antibodies to adeno-associated virus (AAV) occur naturally and block the delivery of life-saving gene therapy. Individuals with antibodies are currently excluded from receiving gene therapies, leaving countless patients with debilitating, terminal genetic disease who cannot receive potentially transformative therapies. Emerging options to reduce neutralizing antibodies include medications that cleave or decrease the lifespan of AAV antibodies or that target plasma cells, however optimal deployment of these approaches will require rapid and robust measurement of AAV antibodies in the clinical setting.
We are seeking a highly motivated and talented Post-Doctoral Scholar to join a brand-new interdisciplinary, industry-academic consortium focused on developing a rapid, robust and reliable assay for AAV antibodies that could be used in the clinic and rapidly incorporate new AAV serotypes and evolved novel AAV capsids. We first plan to use testing platforms to identify which features of pre-existing immunity can predict alterations in safety and efficacy of AAV gene therapies. We next want to compare the attributes of a variety of antibody-measurement technologies (including multiplexed ELISA approaches and mass spectrometry) on standardized positive control antibody cocktails and patient samples from individuals pre- and post-gene therapy administration. We will then leverage these data packets to work with clinicians, scientists and regulators to develop a robust, standardized, platform-based assay that will accelerate testing and enable approaches to modulate antibodies in the clinic. The Post-Doctoral Scholar will be co-advised by Michelle Rengarajan MD, PhD at MGH and Barbara Sullivan PhD, Senior Director of Immunology and Biomarker Strategy at Ultragenyx. The Post-Doctoral scholar will work closely with a diverse team of researchers, including scientists and clinicians from academia and industry to optimize and validate these technologies for detecting AAV antibodies. The role involves applying expertise in molecular biology, immunology, and assay development, while also participating in cross-disciplinary collaborations to advance novel approaches for AAV antibody measurement. Neutralizing antibodies to adeno-associated virus (AAV) occur naturally and block the delivery of life-saving gene therapy. Individuals with antibodies are currently excluded from receiving gene therapies, leaving countless patients with debilitating, terminal genetic disease who cannot receive potentially transformative therapies. Emerging options to reduce neutralizing antibodies include medications that cleave or decrease the lifespan of AAV antibodies or that target plasma cells, however optimal deployment of these approaches will require rapid and robust measurement of AAV antibodies in the clinical setting. We are seeking a highly motivated and talented Post-Doctoral Scholar to join a brand-new interdisciplinary, industry-academic consortium focused on developing a rapid, robust and reliable assay for AAV antibodies that could be used in the clinic and rapidly incorporate new AAV serotypes and evolved novel AAV capsids. We first plan to use testing platforms to identify which features of pre-existing immunity can predict alterations in safety and efficacy of AAV gene therapies. We next want to compare the attributes of a variety of antibody-measurement technologies (including multiplexed ELISA approaches and mass spectrometry) on standardized positive control antibody cocktails and patient samples from individuals pre- and post-gene therapy administration. We will then leverage these data packets to work with clinicians, scientists and regulators to develop a robust, standardized, platform-based assay that will accelerate testing and enable approaches to modulate antibodies in the clinic. The Post-Doctoral Scholar will be co-advised by Michelle Rengarajan MD, PhD at MGH and Barbara Sullivan PhD, Senior Director of Immunology and Biomarker Strategy at Ultragenyx. The Post-Doctoral scholar will work closely with a diverse team of researchers, including scientists and clinicians from academia and industry to optimize and validate these technologies for detecting AAV antibodies. The role involves applying expertise in molecular biology, immunology, and assay development, while also participating in cross-disciplinary collaborations to advance novel approaches for AAV antibody measurement. To apply, please submit your CV and a letter of interest to Jonna Grimsby at jgrimsby@mgb.org. The General Hospital Corporation is an Equal Opportunity Employer. By embracing diverse skills, perspectives and ideas, we choose to lead. All qualified applicants will receive consideration for employment without regard to race, color, religious creed, national origin, sex, age, gender identity, disability, sexual orientation, military service, genetic information, and/or other status protected under law. We will ensure that all individuals with a disability are provided a reasonable accommodation to participate in the job application or interview process, to perform essential job functions, and to receive other benefits and privileges of employment. | |